Development of NMR and thermal shift assays for the evaluation of

Mycobacterium tuberculosis isocitrate lyase inhibitors

Ram Prasad Bhusal, Krunal Patel, Brooke X.C. Kwai, Anne Swartjes, Ghader Bashiri, Jóhannes Reynisson, Jonathan Sperry, Ivanhoe K.H. Leung

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The enzymes isocitrate lyase (ICL) isoforms 1 and 2 are essential for Mycobacterium tuberculosis survival within macrophages during latent tuberculosis (TB). As such, ICLs are attractive therapeutic targets for the treatment of tuberculosis. However, there are few biophysical assays that are available for accurate kinetic and inhibition studies of ICL in vitro. Herein we report the development of a combined NMR spectroscopy and thermal shift assay to study ICL inhibitors for both screening and inhibition constant (IC50) measurement. Operating this new assay in tandem with virtual high-throughput screening has led to the discovery of several new ICL1 inhibitors.

Original languageEnglish
Pages (from-to)2155-2163
Number of pages9
JournalMedChemComm
Volume8
Issue number11
DOIs
Publication statusPublished - 1 Jan 2017
Externally publishedYes

Cite this

Bhusal, R. P., Patel, K., Kwai, B. X. C., Swartjes, A., Bashiri, G., Reynisson, J., ... Leung, I. K. H. (2017). Development of NMR and thermal shift assays for the evaluation of: Mycobacterium tuberculosis isocitrate lyase inhibitors. MedChemComm, 8(11), 2155-2163. https://doi.org/10.1039/c7md00456g
Bhusal, Ram Prasad ; Patel, Krunal ; Kwai, Brooke X.C. ; Swartjes, Anne ; Bashiri, Ghader ; Reynisson, Jóhannes ; Sperry, Jonathan ; Leung, Ivanhoe K.H. / Development of NMR and thermal shift assays for the evaluation of : Mycobacterium tuberculosis isocitrate lyase inhibitors. In: MedChemComm. 2017 ; Vol. 8, No. 11. pp. 2155-2163.
@article{6673633b7d374704b07b6831a2b76f87,
title = "Development of NMR and thermal shift assays for the evaluation of: Mycobacterium tuberculosis isocitrate lyase inhibitors",
abstract = "The enzymes isocitrate lyase (ICL) isoforms 1 and 2 are essential for Mycobacterium tuberculosis survival within macrophages during latent tuberculosis (TB). As such, ICLs are attractive therapeutic targets for the treatment of tuberculosis. However, there are few biophysical assays that are available for accurate kinetic and inhibition studies of ICL in vitro. Herein we report the development of a combined NMR spectroscopy and thermal shift assay to study ICL inhibitors for both screening and inhibition constant (IC50) measurement. Operating this new assay in tandem with virtual high-throughput screening has led to the discovery of several new ICL1 inhibitors.",
author = "Bhusal, {Ram Prasad} and Krunal Patel and Kwai, {Brooke X.C.} and Anne Swartjes and Ghader Bashiri and J{\'o}hannes Reynisson and Jonathan Sperry and Leung, {Ivanhoe K.H.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1039/c7md00456g",
language = "English",
volume = "8",
pages = "2155--2163",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "The Royal Society of Chemistry",
number = "11",

}

Bhusal, RP, Patel, K, Kwai, BXC, Swartjes, A, Bashiri, G, Reynisson, J, Sperry, J & Leung, IKH 2017, 'Development of NMR and thermal shift assays for the evaluation of: Mycobacterium tuberculosis isocitrate lyase inhibitors', MedChemComm, vol. 8, no. 11, pp. 2155-2163. https://doi.org/10.1039/c7md00456g

Development of NMR and thermal shift assays for the evaluation of : Mycobacterium tuberculosis isocitrate lyase inhibitors. / Bhusal, Ram Prasad; Patel, Krunal; Kwai, Brooke X.C.; Swartjes, Anne; Bashiri, Ghader; Reynisson, Jóhannes; Sperry, Jonathan; Leung, Ivanhoe K.H.

In: MedChemComm, Vol. 8, No. 11, 01.01.2017, p. 2155-2163.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Development of NMR and thermal shift assays for the evaluation of

T2 - Mycobacterium tuberculosis isocitrate lyase inhibitors

AU - Bhusal, Ram Prasad

AU - Patel, Krunal

AU - Kwai, Brooke X.C.

AU - Swartjes, Anne

AU - Bashiri, Ghader

AU - Reynisson, Jóhannes

AU - Sperry, Jonathan

AU - Leung, Ivanhoe K.H.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The enzymes isocitrate lyase (ICL) isoforms 1 and 2 are essential for Mycobacterium tuberculosis survival within macrophages during latent tuberculosis (TB). As such, ICLs are attractive therapeutic targets for the treatment of tuberculosis. However, there are few biophysical assays that are available for accurate kinetic and inhibition studies of ICL in vitro. Herein we report the development of a combined NMR spectroscopy and thermal shift assay to study ICL inhibitors for both screening and inhibition constant (IC50) measurement. Operating this new assay in tandem with virtual high-throughput screening has led to the discovery of several new ICL1 inhibitors.

AB - The enzymes isocitrate lyase (ICL) isoforms 1 and 2 are essential for Mycobacterium tuberculosis survival within macrophages during latent tuberculosis (TB). As such, ICLs are attractive therapeutic targets for the treatment of tuberculosis. However, there are few biophysical assays that are available for accurate kinetic and inhibition studies of ICL in vitro. Herein we report the development of a combined NMR spectroscopy and thermal shift assay to study ICL inhibitors for both screening and inhibition constant (IC50) measurement. Operating this new assay in tandem with virtual high-throughput screening has led to the discovery of several new ICL1 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85034218320&partnerID=8YFLogxK

U2 - 10.1039/c7md00456g

DO - 10.1039/c7md00456g

M3 - Article

VL - 8

SP - 2155

EP - 2163

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 11

ER -